Pfizer's tyrosine kinase inhibitor Inlyta is already a cornerstone of treatment for some forms of cancer, but could have potential as a therapy for Alzheimer's disease as well, according to
Biogen and Eisai's first Alzheimer's disease drug Aduhelm is facing an uphill battle in the US market, but the partners are forging ahead with their second candidate lecanemab, starting a r
A digital health company focusing on neurodegenerative disorders – Neuroglee Therapeutics – has raised $10 million in first-round funding to roll out a virtual neurology clinics for people
Shares in Biogen have come under pressure after chief executive Michel Vounatsos admitted that the company is facing a much slower than anticipated rollout of its controversial Alzheimer's
Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer's disease candidate semorinemab hit one of its objectives in a phase 2 trial, although it missed another.
Health insurer Excellus BlueCross BlueShield has said it will not cover treatment with Biogen and Eisai's new Alzheimer's disease drug Aduhelm because it has not been shown to be medically
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.